Sorafenib for patients with advanced angiosarcoma: a phase II Trial from the French Sarcoma Group (GSF/GETO).
about
Pazopanib in the management of advanced soft tissue sarcomasAdvances and controversies in the management of soft tissue sarcomas.Clinical and endoscopic features of angiosarcoma of the colon: two case reports and a review of the literature.The evolution of systemic therapy in sarcoma.Sorafenib in patients with locally advanced and metastatic chordomas: a phase II trial of the French Sarcoma Group (GSF/GETO)Clinical practice guidelines for the diagnosis and treatment of patients with soft tissue sarcoma by the Spanish group for research in sarcomas (GEIS).Phase II studies in soft tissue sarcoma: time for reappraisal.Aberrations in Angiogenic Signaling and MYC Amplifications are Distinguishing Features of Angiosarcoma.Emerging therapies for adult soft tissue sarcoma.Fulminant hepatic failure secondary to primary hepatic angiosarcoma.Targeted therapy in sarcomas other than GIST tumorsMonitoring chemotherapeutic response by hyperpolarized 13C-fumarate MRS and diffusion MRI.Comprehensive establishment and characterization of orthoxenograft mouse models of malignant peripheral nerve sheath tumors for personalized medicine.Primary and secondary angiosarcomas: a comparative single-center analysis.New systemic therapy options for advanced sarcomas.Inefficiencies and Patient Burdens in the Development of the Targeted Cancer Drug Sorafenib: A Systematic ReviewSystemic treatment in advanced soft tissue sarcoma: what is standard, what is new.Alliance A091103 a phase II study of the angiopoietin 1 and 2 peptibody trebananib for the treatment of angiosarcoma.New drugs and combinations for the treatment of soft-tissue sarcoma: a review.Targeted massively parallel sequencing of angiosarcomas reveals frequent activation of the mitogen activated protein kinase pathwayRecurrent CIC Gene Abnormalities in Angiosarcomas: A Molecular Study of 120 Cases With Concurrent Investigation of PLCG1, KDR, MYC, and FLT4 Gene Alterations.Angiosarcoma outcomes and prognostic factors: a 25-year single institution experience.Prognostic Significance of Forkhead Box M1 (FOXM1) Expression and Antitumor Effect of FOXM1 Inhibition in Angiosarcoma.Expression of angiopoietin-TIE system components in angiosarcomaCombination targeted therapy of VEGFR inhibitor, sorafenib, with an mTOR inhibitor, sirolimus induced a remakable response of rapid progressive Uterine PEComa.Angiosarcoma originating from an ovarian mature teratoma, a rare disease with complex treatment modalities.Primary Angiosarcoma of the Spleen: Rare Diagnosis with Atypical Clinical CourseTargeted therapy for sarcomas.Histology-specific therapy for advanced soft tissue sarcoma and benign connective tissue tumors.Angiosarcoma of small bowel presenting with obstruction: novel observations on a rare diagnostic entity with unique clinical presentation.Risk of hypertension in cancer patients treated with sorafenib: an updated systematic review and meta-analysis.Antiangiogenic approach in soft-tissue sarcomas.New and emerging therapies for advanced or metastatic soft tissue sarcoma.Primary hepatic angiosarcoma and potential treatment options.Role of genetic and molecular profiling in sarcomas.Angiosarcoma: A rare malignancy with protean clinical presentations.Sorafenib: 10 years after the first pivotal trial.Current and advancing systemic treatment options for soft tissue sarcomas.Targeted therapy and promising novel agents for the treatment of advanced soft tissue sarcomas.Cutaneous angiosarcoma of the head and face: a single-center analysis of treatment outcomes in 43 patients in Japan.
P2860
Q26746205-1C12281A-254F-451B-98D8-55EBDC4BEEE8Q30240228-932C3EC8-6E6C-4657-9B87-3151A64104ACQ33162353-42770BB0-A07D-479C-A5DD-2A4F8AAEA60FQ33274710-AF691827-2ECC-4807-8AF9-1A7E5B03EA39Q33275688-874FEB0E-DB4F-4009-B04C-68692C87CE78Q34045393-F36F49BC-BF88-41CE-A861-7B03759910A1Q34143849-E3015A8C-E4D9-42FE-AE3B-DFAE15C5EED2Q34443645-B3F101F8-CC08-4E83-90AF-488C3AE61539Q34659806-94104408-2859-4448-8FCF-52291916DD85Q35178148-682C0ADB-5880-40C4-9957-CB9C0C02E916Q35622367-C2887FAF-6EA9-40BD-882F-AF1C67B005EEQ35703167-A5326D6D-15CA-476C-87DF-7BAD9182CA12Q35822579-6DB077B2-A2AF-4E1C-9978-CDC691684678Q36091977-561C7FBB-F37B-4036-A650-4BA6A270D842Q36166394-0E2DF10F-6AE7-4909-B2CA-AE519EC0E9F7Q36270115-D2AC91C4-1F8B-4EAA-803F-8028DBA4595EQ36389964-79483A28-A712-4BB0-9310-B334CA20F11CQ36425904-6477B901-91FE-4E86-A36C-705B7F421E84Q36444369-2C20E09C-B300-4129-95F8-9447223E06E4Q36546559-65ACAF9B-C5DE-4CB6-B0FE-DF172375A891Q36803294-AB3B90D1-076C-42FA-9FB9-448F4CD22A46Q36876315-01618C88-EB02-48A6-91C1-3CE8EFEC99D1Q36882572-3E7FAF3A-6E9F-450A-A3CA-07685A231C25Q36997066-7414D577-7893-462A-86DB-D869AFEF26CDQ37187778-225F2517-3B9E-420E-9388-2DC73D4239A5Q37390343-9FE9EC36-47CB-4CAF-B5AC-415ABB3A6185Q37404756-656483AA-C443-4031-B955-5915AB9F5AF1Q37655450-8B9F55B0-0B31-4045-9A62-4EC7EBD2A014Q38011606-9D232FF7-C0BF-4E0D-ADF9-C4B51F380DFFQ38063861-53C12CC1-A007-4077-8265-D92CA745FB81Q38103397-796985E9-A7DB-41C3-83B0-DEC535EA41ADQ38128896-BE43122F-C18F-43B2-A3E6-6FC49A7A845FQ38136098-AA05EAF9-870A-41E7-BE08-C85883321702Q38174195-7504BF7F-AB1A-4B88-BCA9-D3DF566BF770Q38458016-557DA926-118C-435C-9C6F-584DB4E67CCDQ38510830-635DDB51-A535-4A18-8E79-183D92C770E2Q38544841-1B8FBDB5-D834-4593-9DB4-03E358849700Q38563242-66EFF9DB-540A-4FD8-BF1F-9675E3C3886DQ38569799-B608C843-ED21-4797-AABC-8180D69E1A0CQ38789136-9CCCF1FD-C4ED-4A9B-B12B-FCD342C08703
P2860
Sorafenib for patients with advanced angiosarcoma: a phase II Trial from the French Sarcoma Group (GSF/GETO).
description
2012 nî lūn-bûn
@nan
2012年の論文
@ja
2012年論文
@yue
2012年論文
@zh-hant
2012年論文
@zh-hk
2012年論文
@zh-mo
2012年論文
@zh-tw
2012年论文
@wuu
2012年论文
@zh
2012年论文
@zh-cn
name
Sorafenib for patients with ad ...... ench Sarcoma Group (GSF/GETO).
@ast
Sorafenib for patients with ad ...... ench Sarcoma Group (GSF/GETO).
@en
type
label
Sorafenib for patients with ad ...... ench Sarcoma Group (GSF/GETO).
@ast
Sorafenib for patients with ad ...... ench Sarcoma Group (GSF/GETO).
@en
prefLabel
Sorafenib for patients with ad ...... ench Sarcoma Group (GSF/GETO).
@ast
Sorafenib for patients with ad ...... ench Sarcoma Group (GSF/GETO).
@en
P2093
P2860
P50
P1433
P1476
Sorafenib for patients with ad ...... ench Sarcoma Group (GSF/GETO).
@en
P2093
Antoine Italiano
Charles Fournier
Christine Chevreau
Didier Cupissol
Emmanuelle Bompas
Eric Gauthier
French Sarcoma Group (GSF/GETO)
Guilhem Bousquet
Laurent Lemaitre
Nicolas Isambert
P2860
P304
P356
10.1634/THEONCOLOGIST.2011-0237
P50
P577
2012-01-27T00:00:00Z